Pfizer Forecasts $9.7B Cost Savings and Beats Quarterly Results
Pfizer expects $9.7 billion in net savings from cost reductions through 2029 to offset declining Covid-related revenue and support sustainable growth. The company reported a quarterly results beat, with Eliquis and Padcev sales exceeding estimates, and lifted its full-year sales range to $60.5–$62.5 billion. CEO Bourla plans to keep the dividend and resume increases, while Dave Denton is set to leave as CFO as investors track late-stage cancer and obesity-drug data.